Introduction
Malignant transformation of hematopoietic cells involves the dysregulation of genes that are normally involved in regulating proliferation and survival. The mechanism of how such dysregulation can summate to transform cells is still unclear. The Pim-1 and Pim-2 oncogenes have been implicated in the transformation of both T and B lymphocytes 1, 2 , but the mechanism by which dysregulated expression of Pim kinases promotes the development of hematopoietic tumors has not been defined.
The Pim-1 gene was originally identified as a proviral insertion site of the Moloney Murine Leukemia Virus (MoMuLV) in lymphomas in mice 1 . Subsequently, Pim-2 and Pim-3 were cloned and these three proteins constitute a distinct family of serine/threonine kinases. Increased expression of Pim kinases has been demonstrated in several different types of human tumors, including lymphomas, prostate cancer and oral cancer [3] [4] [5] [6] [7] . A high frequency of mutation in the Pim-1 gene has been observed in diffuse large B cell lymphoma cases 2, 8 . Importantly, experiments using transgenic mouse models have demonstrated that overexpression of Pim-1 or Pim-2 predisposes the mice to the development of lymphoid tumors 9, 10 . In addition, the Pim family of kinases has been implicated in the development of other types of human hematopoietic malignancies as well. Overexpression of Pim-1 has been observed in acute myeloid and erythroid leukemias 6 . These data suggest that dysregulation of Pim expression may be a common occurrence during transformation of a variety of cell types.
How then do Pim kinases propagate signals that promote tumorigenesis and why are elevated levels of Pim kinases important for the formation of hematopoietic malignancies? Pim-1, Pim-2, and Pim-1/Pim-2-deficient mice all show only minor
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From phenotypic aberrations 11, 12 . Mice deficient for all three Pim kinases display reduced body size and impaired responses to hematopoietic growth factors 13 . Little is known about the functional role of the Pim kinases in vivo, although a number of observations have pointed to a potential role for Pim-1 in signal transduction. Pim kinases have also been demonstrated to act on several cellular substrates including BAD, NFATc, Cdc25A, and SOCS-1 [14] [15] [16] [17] . In addition, recent data suggests that Pim can phosphorylate Cot, a regulator of I-κB function 18 . This appears to be important in the increased activation of NF-κB in some transformed lymphocytes 18 . However, the precise role of Pim-mediated modification of these substrates in cellular transformation is not fully understood.
Interestingly, recent studies have showed that the expression of Pim-1 is induced by BCR-Abl-activated STAT5 19, 20 . Up-regulation of Pim expression may play an important role in cellular transformation mediated by BCR-Abl 19, 21 . However, a study from another group demonstrated that although Pim-1 was markedly up-regulated following activation of STAT5, the expression of Pim-1 is dispensable for transformation by BCR-Abl 22 . Because these studies utilized growth factor-dependent cell lines such as Ba/F3 and FDCP1, the importance of Pim kinases for Abl-mediated transformation remains to be further elucidated.
To better understand the role of Pim kinases in Abl-mediated transformation, we have carried out studies of their expression and functional involvement in pre-B cell tumorigenesis by using wild-type and Pim-deficient cells. These studies demonstrate that Pim deficiency has profound effects on the v-Abl transformation. Pim kinases are involved in multiple pathways that affect v-Abl-mediated transformation. First, Pim kinases are involved in SOCS-1 modification and in regulation of SOCS-1 protein levels 
Materials and methods
V-Abl-mediated transformation and cell culture. Bone marrow or fetal liver transformation was performed and v-Abl-transformed pre-B cell lines were generated and cultured as described previously 23 . Briefly, cells were infected with free viruses by spin infection. Infected cells were seeded in 96-well plates, and transformation efficiency was scored by counting the number of wells that displayed cytokine-independent growth two weeks post-infection.
Plasmids and retroviral vectors. The bicistronic retroviral vector containing p120v-Abl and GFP was a gift from Dr. Naomi Rosenberg (School of Medicine, Tufts University).
The GFP sequence was excised from the construct, and either Pim-1, Pim-2, or Pim-3 coding DNAs were subcloned into the BsaB I/Mfe I sites to generate p120v-Abl-IRESPim1, p120v-Abl-IRES-Pim2, and p120v-Abl-IRES-Pim3. Either wild-type or kinasedead mutation (K67M) of human Pim-1 were subcloned into pMSCV-IRES-EGFP (pMIG) to generate pMIGPim-1 and pMIGPim-1KD. The bicistronic retroviral vector expressing p120v-Abl and SOCS-1 has been previously described 23 .
Antibodies. The following antibodies were used for Western blotting or immunoprecipitation: Anti-Pim-1, anti-Pim-2 and anti-Bcl-XS/L (Santa Cruz Biotechnology), anti-Abl AB-2 and AB-3 (CalBiochem), anti-X-press (Invitrogen), anti-BAD and anti-phospho-BAD (Ser112) (Cell Signaling), anti-actin, anti-flag and anti-HA (Sigma-Aldrich). All other antibodies were obtained as described previously 17, 23 .
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Cytokine and inhibitor treatments of cells. IFN-γ was purchased from BD Biosciences and used at a concentration of 50 ng/ml for cell stimulation. For cycloheximide (SigmaAldrich) time course experiments, the final concentration of cycloheximide was 100 µg/ml. For LLNL (N-acetyl-leu-leu-norleucinal, Sigma-Aldrich) treatments of cells, LLNL was used at concentrations of 1 µM or 5 µM as indicated. Imatinib was a generous gift from Novartis. Pre-B cell lines were treated with 1 µM imatinib for 4 hours, unless otherwise indicated.
Cell extracts, immunoprecipitation, and Western blotting. Cell extracts were prepared and immunoprecipitations were performed also as previously described 17, 23 . Samples were then analyzed by Western blotting. Where indicated Western blot signals were quantified by densitometry.
Flow cytometry and apoptosis assay. Cells were washed extensively in medium and cultured with imatinib for the indicated times. For double staining with propidium iodide (PI) (Sigma-Aldrich) and Annexin V (Molecular Probes), cells were washed extensively with ice-cold PBS, and the samples were resuspended in PBS containing 2.5 µg/mL Annexin V, 1 µg/mL PI, 1mM MgCl2 and 1.8 mM CaCl2. Then the samples were analyzed by fluorescence-activated cell sorter. In some cases, cell viability was also assessed by counting the Trypan Blue negative cells serially. It has been demonstrated that by binding its C-terminal SOCS box to the Elongin BC complex, SOCS-1 becomes part of an E3 enzyme and serves to target bound protein substrates such as Jak kinases to proteasomal degradation 24 . Because our results suggest that Pim kinases associate with SOCS-1, we explored whether SOCS-1 has an inhibitory effect on the levels of Pim-1 and Pim-2. To this end, we used the A-MuLV-transformed pre-B cell lines derived from SOCS-1-deficient mice and wild-type littermates. No significant differences in the protein levels of Pim-1 and Pim-2 were observed between A-MuLV-transformed wild-type and SOCS-1 -/-cells treated with or without imatinib (Fig. 3C ). These data suggest that expression of SOCS-1 has no effect on the levels of Pim-1 and Pim-2 in v-Abl transformants. When the cells were treated with IFNγ alone, the levels of Pim-1 and Pim-2 in wild-type cells were still comparable to those found in SOCS-1 -/-cells (Fig. 3D) . These results are consistent with our previous observations indicating that SOCS-1 function is impaired by v-Abl so that it does not inhibit JAK/STAT signaling that mediates Pim expression 25 . In order to test the effect of SOCS-1 on cytokine-induced Pim expression, we inactivated Abl kinase with imatinib. As shown in figure 3D , wild-type cells ( Fig. 4A and 4B ). The effect of Pim kinase deficiency on SOCS-1 protein levels can be reversed by adding LLNL, a proteasome inhibitor, to the cells (Fig. 4C ).
Studies using confocal microscopy showed that distribution of SOCS-1 in the (Fig. S2A ). These observations demonstrate that a reduction in the amount of SOCS-1 protein is due to increased proteasomal degradation in the absence of Pim kinases.
Next, we estimated the relative half-life of SOCS-1 protein expressed in v-Abl- (table 1) .
Furthermore, we found that v-Abl transformants derived from these triple knockouts only survived for 5 weeks under cytokine-independent conditions. These data suggest that in addition to their role in regulating SOCS-1 function, Pim kinases play other potential role in v-Abl transformation, likely related to apoptosis.
For hrs, respectively. As expected, time course studies showed that the levels of Pim-1 and Pim-2 in wild-type cells dramatically decreased after treatment with imatinib for 5 hrs or longer (data not shown). After inhibition of the Abl kinase, the expression of Bcl-XL was also markedly downregulated ( Fig. 5D) , consistent with the earlier observations 26, 27 . Importantly, the level of Bcl-XS increased by approximately 2.5-fold in wild-type cells cultured in the presence of imatinib (Fig. 5D ), which is in striking contrast to the reduced Bcl-XL level. However, the BCL-XS level was only slightly increased in Pim-1 -/-/Pim-2 -/-/Pim-3 -/-cells cultured under the same conditions (Fig. 5D) . Together, these results suggest a negative role for Pim kinases induced by v-Abl in the production of BCL-XS in v-Abl transformants. (Fig. 6A) . The survival promoting effect of Pim-1 was dependent on catalytic activity, as the cells expressing kinase-dead Pim-1KD recapitulated that of the empty vector control (Fig. 6A) . These results indicate that when constitutively expressed in v-Abl-transformed cells, Pim-1 conferred apoptotic resistance to imatinib stimulus.
Ectopic overexpression of Pim-1 increases the resistance of v-Abl-transformed cells to apoptosis induced by imatinib
We next examined whether ectopic expression of Pim-1 was sufficient to regulate Bcl-XS protein expression. As shown in figure 6B , in Pim-1 -/-/Pim-2 -/-/Pim-3 -/-cells, constitutively expressing Pim-1 decreased the amount of Bcl-XS protein to the levels observed in wild-type cells. Expression of either Pim-1KD or empty vector had no effect on Bcl-XS levels, confirming a requirement for the kinase activity (Fig. 6B ). These
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Pim kinases increase phosphorylation level of BAD in v-Abl-transformed cells
It has been documented that Pim kinases can phosphorylate Ser112 of BAD, the proapoptotic member of Bcl-2 family, and thereby block BAD-induced apoptosis 15, 28, 29 .
Hence, we explored whether Pim kinase deficiency could decrease BAD phosphorylation. Indeed, the amount of phospho-Ser112 BAD was markedly reduced in For
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Our experiments have also begun to address the mechanism by which Pim may affect Abl transformation. We observed that Pim kinases are involved in regulating protein stability and phosphorylation of SOCS-1 in v-Abl transformants. A recent study from others also demonstrates that tyrosine phosphorylation of SOCS-3 inhibits turnover of SOCS-3 protein and renders it unable to normally regulate JAK2 kinase 30 
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